Identifying the Toxidrome of Ivermectin Toxicity.
activated charcoal
covid-19
ivermectin
prophylaxis and treatment
toxicity
Journal
Cureus
ISSN: 2168-8184
Titre abrégé: Cureus
Pays: United States
ID NLM: 101596737
Informations de publication
Date de publication:
Jul 2023
Jul 2023
Historique:
accepted:
28
07
2023
medline:
29
8
2023
pubmed:
29
8
2023
entrez:
29
8
2023
Statut:
epublish
Résumé
Ivermectin is an antiparasitic drug that has been used as an alternative for prophylaxis and treatment of COVID-19 infection. The adverse effects from supratherapeutic doses of ivermectin can include non-neurological and neurological symptoms. In this study, we report the case of a 52-year-old Filipino male with newly diagnosed diabetes mellitus who developed a subacute history of fever, cough, and generalized weakness, causing him to self-medicate with supratherapeutic doses of ivermectin and thereafter subsequently developed a decrease in sensorium, restlessness, and complex visual hallucinations. Significant laboratory examinations showed hyperglycemia, mild hyponatremia, positive SARS-CoV2 reverse transcriptase polymerase chain reaction test, and bilateral pneumonia on chest radiograph. He was subsequently started on antibiotics, a high-flow nasal cannula, and given two doses of activated charcoal. During the first 24 hours of hospital admission, there was a significant improvement in the patient's sensorium with a resolution of restlessness and visual hallucinations. During the rest of the hospitalization, his respiratory symptoms improved, and he was subsequently discharged. Clinical outcome in our patient after administration of activated charcoal and completion of antibiotics showed an overall improvement in symptoms and without any neurologic sequelae.
Identifiants
pubmed: 37641774
doi: 10.7759/cureus.42603
pmc: PMC10460504
doi:
Types de publication
Case Reports
Langues
eng
Pagination
e42603Informations de copyright
Copyright © 2023, Dy et al.
Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Filaria J. 2003 Oct 24;2 Suppl 1:S8
pubmed: 14975065
Am J Trop Med Hyg. 2018 Feb;98(2):382-388
pubmed: 29210346
N Engl J Med. 2020 Aug 20;383(8):787-789
pubmed: 32813957
Fundam Clin Pharmacol. 2021 Apr;35(2):260-276
pubmed: 33427370
PLoS Negl Trop Dis. 2021 Apr 20;15(4):e0009354
pubmed: 33878105